On 4/22/19, Gritstone Oncology filed for a $102 Million offering of its common stock. Gritstone trades on NASDAQ under the symbol, “GRTS.” The company currently has a market cap of $394 Million.
Gritstone is developing personalized immunotherapy to fight multiple types of cancer. They have developed an AI platform named, “EDGE” to aid their development efforts. The company is currently in the clinical stage and has four development programs. Its lead product, Granite-001, is in Ph I/II trials.
Granite-001 is a personalized neoantigen based immunotherapy. It has received fast track designation from the FDA for the treatment of colorectal cancer.
As of this writing the stock is down 7.63 percent.